Overview
TRIMERIC HIV-1 ENVELOPE GLYCOPROTEIN IMMUNOGENS
We use our accumulated knowledge of the structure and function of the HIV-1 envelope (Env) glycoprotein trimer to design and evaluate recombinant forms of these proteins as immunogens for vaccine development. In the initial stages of the virus replication cycle, the envelope glycoproteins attach HIV-1 to its susceptible target cells, which are predominantly CD4-positive T-cells, macrophages and dendritic cells. The Env trimer then undergoes a series of receptor-mediated conformational changes that enable the virus and cell membranes to fuse, and the virus to infect the cell. The Env glycoproteins are also critical targets for host immunity, particularly virus neutralizing antibodies (NAbs). These antibodies bind to functional Env glycoproteins on the virus surface and block their activity. Inducing broadly active NAbs by immunization with Env glycoproteins would, therefore, be a valuable component of a vaccine to prevent HIV-1 infection. To this end, we have designed and are developing stable, recombinant trimers that faithfully mimic the native, functional trimers that are present on the virus surface. These trimers, called SOSIP glycoproteins, induce narrow-specificity NAbs in test animals, and we are working to broaden these responses. All of this work is carried out as part of a multi-disciplinary team with colleagues in other institutions, including structural biologists and immunologists.
Highlights
- 1
- 2Pathogens & immunity · 2021
- 3Journal of virology · 2020
Publications
Funding
Active
7 grants- PITargeting germline-bNAbs via SOSIP trimers;National Institute of Allergy and Infectious Diseases · 2026–2031P01AI197052-01
- Co-IAn early life multivalent immunization strategy for induction of neutralization breadthNational Institute of Allergy and Infectious Diseases · 2025–2030U01AI192448-02
- Co-ITranslating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early lifeNational Institute of Allergy and Infectious Diseases · 2025–2030P01AI189362-02
- PINeutralization of primary HIV-1 virusesNational Institute of Allergy and Infectious Diseases · 2018–2028· 2 renewalsR01AI036082-34
- Sub-PIINV63951 - Trimer based germline-targeting immunization to induce HIV-1 bNAbs - AUMCBill & Melinda Gates Foundation · 2025–2026 · via Amsterdam University Medical CentersINV-063951
- PICleaved, stabilized HIV-1 Env trimers for structural and vaccine studiesNational Institute of Allergy and Infectious Diseases · 2015–2026· 3 renewals
- PIINV091003 Targeting germline-bNAbs via SOSIP trimersBill & Melinda Gates Foundation · 2025–2026BMGF INV-091003
Completed grants (19)
- Sub-PIPhase 1 study of BG505 SOSIP Trimer boosting in GT1.1 primed individualsBill & Melinda Gates Foundation · 2023–2025 · via Rockefeller UniversityINV-048573
- Sub-PIPhase 1 clinical study testing GT1.1 trimerBill & Melinda Gates Foundation · 2019–2024 · via Rockefeller UniversityINV-008818
- Sub-PIDesign HIV Trimer Immunogens to Elicit bNAbs Aimed at two EpitopesBill & Melinda Gates Foundation · 2019–2023 · via Amsterdam University Medical CentersINV-002022
- PINext Generation BG505 SOSIP.664-trimer Based HIV VaccinesBill & Melinda Gates Foundation · 2016–2020OPP1132237-03
- PIHIV-1 Monoclonal AntibodiesUniversity of Maryland, Baltimore · 2019–2020UMB 194671-01
- Sub-PIStructure Based Immunogen Design at UW-IPDBill & Melinda Gates Foundation · 2018–2020 · via University of Washington, TheOPP1156262
- Sub-PIDevelopment of Nearest Neighbor Immunogens for HIV-1 VaccinesBill & Melinda Gates Foundation · 2014–2019 · via University of Washington, TheOPP1111923
- PINeutralization of Primary HIV-1 VirusesNational Institute of Allergy and Infectious Diseases · 2008–2018· 2 renewalsR37AI036082-25
- Sub-PICenter for HIV/AIDS Vaccine Immunology and Immunogen DiscoveryNational Institute of Allergy and Infectious Diseases · 2013–2016 · via Scripps Research InstituteUM1AI100663-04
- PISecond Receptors for Primate Immunodeficiency VirusesNational Institute of Allergy and Infectious Diseases · 2011–2016R01AI041420-20
- PIA practical microbicide based on HIV-1 entry inhibitorsNIAID · 2008–2013 · via NIH RePORTER
- PIModified envelope glycoproteins for HIV-1 vaccineNIAID · 1999–2011 · via NIH RePORTERR01AI045463-13
- PICORE--INHIBITOR ACQUISITION, EVALUATION AND FORMULATIONNIAID · 2005–2009 · via NIH RePORTERU19AI065413-03
- PIViral Host And Combinational Influences on PRO 140NIAID · 2006–2009 · via NIH RePORTERU19AI066329-04
- PIENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1NIAID · 2001–2005 · via NIH RePORTERP01AI052048-04
- PICHRYSTALLIZING DISULFIDE-STABILIZED HIV-1 ENV PROTEINSNIAID · 2003–2005 · via NIH RePORTERR21AI054159-02
- PIHIV NEUTRALIZATION IN VITRO & IN SHIV-INFECTED MACAQUESNHLBI · 1997–2002 · via NIH RePORTERR01HL059735-06
News mentions
- NIH Grant Aims for Childhood Vaccine Against HIVSeptember 18, 2025
A multi-institutional team led by Weill Cornell Medicine investigators has been awarded a five-year, $20.8 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for advanced preclinical development of a promising experimental HIV vaccine.
- The Quest for an HIV VaccineAugust 20, 2025
Along with an international team, Dr. John Moore, has brought biomedicine closer than ever to an HIV vaccine.
- Childhood HIV Vaccination Strategy Shows Promise in StudyAugust 30, 2024
Research at Weill Cornell Medicine suggests that childhood immunization against HIV could one day provide protection before risk of contracting this potentially fatal infection dramatically increases in adolescence.
Media highlights
- How Fauci Went From 'Icon' During AIDS Crisis To COVID Lightning RodUSA Today · August 11, 2026
Mentoring
- DCDevidas ChaturbhujPostdoc mentee · 2020–2025